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ABSTRACT 
Objective: Hyponatremia (HN) is associated with mortality and morbidity risks due to the development of hyponatremic encephalopathy. Its rapid 
correction also carries a high risk of development of the serious cerebral disorder. This study investigated the possible therapeutic and 
neuroprotective effects of the green tea (GT) extract against HN and its complications in rats and compared those effects with the outcome of the 
rapid correction of chronic HN using hypertonic saline (HtNaCl).  
Methods: Chronic HN was induced using terlipressin (TP; 0.2 mg/kg, s. c) and 2.5% d-glucose solution (equivalent to 5% initial bw/day, i. p) for 3 d. 
A stabilizing dose of TP (0.1 mg/kg) was used for the following 3 d, along with administration of either saline, GT (600 mg/kg/day, p. o), or HtNaCl 
(15 ml/kg/day, i. p). Serum sodium level, locomotor activity, pain reflex, and brain contents of iNOS and NO were assessed, together with a 
histopathological examination of brain tissues.  
Results: TP-induced profound chronic HN that was corrected with administration of GT and HtNaCl. In a GT-treated group, correction of HN was 
coupled with improvement of TP-induced alteration of locomotor activity and brain histopathological picture. Elevation of brain iNOS and NO 
contents, along with detection of focal cellular necrosis and gliovascular proliferation changes in the HtNaCl-treated group indicated neuro 
pathological complications are accompanying the correction of HN with HtNaCl; a result that was not found in the GT-treated group.  
Conclusion: Our findings revealed that GT corrected HN induced by TP in rats, and protected against the neuropathological features that 
characterized hyponatremic encephalopathy and accompanied with its rapid correction.  
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INTRODUCTION 
Hyponatremia (HN) is defined as a decrease in serum sodium 
concentration to a level below 136 mmol/l [1]. It is the most 
common electrolyte disorder occurring in 15–30% of hospitalized 
patients [2]. Etiologies of HN include renal and extra-renal loss of 
sodium with water retention as in cases of mineralocorticoid 
deficiency, autoimmune diseases, adrenal hemorrhage, muscle 
trauma, burns, sweat losses, and gastrointestinal losses due to 
vomiting and diarrhea [3]. Moreover, various pharmacological 
agents are known to be associated with induction of HN, including, 
narcotics, sedatives, analgesics, hypoglycaemic agents, anti-
neoplastic drugs, and antidepressants [4, 5]. HN can also arise in a 
variety of diseases such as congestive heart failure, liver cirrhosis, 
and renal failure whether acute or chronic [6]. The most common 
cases of HN include exercise-associated HN, particularly in athletes 
who participate in endurance events [7], ecstasy-associated HN [8], 
and postoperative HN [9]. 
HN is physiologically significant when it indicates a state of 
extracellular hypo-osmolality and a tendency for free water to shift 
from the vascular space to the intracellular space. However, 
although cellular edema is well tolerated by most tissues, it is not 
tolerated in the brain as its maximum swelling is limited to 8% 
secondary to the presence of the rigid calvarium [3]. In severe HN, 
this cytotoxic cerebral edema results in the development of 
hyponatremic encephalopathy, which is a medical emergency that 
can be lethal [10]. The rate of development of HN plays a critical role 
in its pathophysiology and subsequent treatment [11]. In acute HN 
that is developed rapidly over a period of hours (<48 h), a more 
severe degree of cerebral edema for a given serum sodium level 
results. Thus, it occurs with alarming hyponatremic encephalopathy 
findings, and the primary cause of morbidity and death is brainstem 
herniation and mechanical compression of vital midbrain structures 
[12]. In chronic HN, when serum sodium concentration falls slowly 
over a period of several days or weeks (≥ 48 h), a slower process of 
adaptation then occurs in which the brain cells extrude sodium and 
potassium as well as organic solutes including phosphocreatine, 
myoinositol, and amino acids, such as glutamine and taurine, from 
their cytoplasm to the extracellular space [13]. Compensatory 
extrusion of solutes allows intracellular osmolality to be equal to 
plasma osmolality and, in turn, reduces the flow of free water into 
the intracellular space [14]. Therefore, brain swelling is minimized 
with more modest symptoms and cases, almost, never die from 
brain herniation [14]. However, the principal causes of morbidity 
and death in chronic HN are status epilepticus, when chronic HN 
reaches levels of 110 mmol/l or less, and osmotic demyelination 
syndrome (ODS), which occurs in association with rapid correction 
of chronic HN [11]. ODS is characterized by focal destruction of 
myelin sheaths that cover axons in the brainstem, in the pontine and 
extrapontine areas, associated with serious neurologic sequelae 
[15]. Several lines of evidence have linked the pathogenesis of 
myelinolysis to the slow reuptake of organic osmolytes by the brain. 
[16, 17]. 
Treatment of HN consists of free water restriction and correction of 
the underlying condition. The daily fluid intake must be restricted to 
less than the urine output volume and the insensible losses of water 
during 24 h in order to cause a negative water balance and increase 
serum sodium concentration [3]. Some cases of chronic HN do not 
tolerate or comply with this degree of daily fluid restriction. In these 
cases, the use of diuretics that increase electrolyte-free water 
excretion may be added to the treatment protocol [18-20]. 
Green tea (GT) is a popular worldwide beverage that has been 
shown to possess several pharmacological activities [21-24]. It has 
been reported for its diuretic [25-28], anti-inflammatory [29], 
antiarthritic [30], antibacterial [31], antiviral [32], antiproliferative 
[33], antioxidant [34,35], neuroprotective [36, 37], and cholesterol-
lowering effects [23, 38, 39]. Moreover, consuming green tea has 
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been found to protect against obesity [40, 41], cancer [42, 43], and 
cardiovascular diseases [44-46]. The chemical composition of green 
tea is complex; it contains xanthic bases (caffeine and theophylline), 
polyphenols commonly known as catechins, pigments, volatile 
compounds, proteins, amino acids, carbohydrates, vitamins (B, C, E), 
minerals, trace elements, and trace amounts of lipids and sterols [23, 24, 
45]. Caffeine and theophylline account for the diuretic effect of GT [25-
28]. It has been demonstrated that caffeine could increase urine 
production in patients with congestive heart failure and edema; 
however, theophylline has been found to induce even higher diuretic 
effect than caffeine [47, 48]. On the other hand, GT polyphenols are 
responsible for the neuroprotective and the antioxidant properties of GT. 
The present study aimed at testing the possible protective effects of GT 
extract against chronic HN and hyponatremic encephalopathy induced 
in rats using terlipressin (triglycyl–lysine vasopressin; TP), which is a 
long-acting analog of the antidiuretic hormone, vasopressin (VP) [49]. 
Moreover, the study compared the effects of GT with those resulted from 
the rapid correction of chronic HN using hypertonic saline (HtNaCl). 
MATERIALS AND METHODS 
Animals 
Adult male albino Wister rats, weighing 180–200 g, was utilized in the 
present study. Standard food pellets and tap water were supplied ad 
libitum unless otherwise stated. Animals and food pellets were obtained 
from the animal house colony of the National Research Center (NRC, 
Egypt). Ethical considerations in handling laboratory animals that stated 
by NRC were followed throughout the study period. 
Drugs 
TP vials (Glypressin®; Ferring Pharmaceuticals, Germany) were 
used in the current study. GT water extract, in the form of powder, 
was obtained from Technomate for Chemicals and Pharmaceuticals 
(Egypt), and was used orally in a dose of 600 mg/kg/day [35]. All 
other chemicals were of the highest available commercial grade. 
Experimental design 
Chronic HN was induced in rats according to the method established 
in our previous study with colleagues [49]. The animals were 
randomly allocated into four groups; each group consisted of 10 
rats. During the induction phase of this experiment (days 1–3), rats 
of the first group received s. c injections of saline and served as the 
normal group. In the remaining three groups, chronic HN was 
induced by injections of TP (0.2 mg/kg/day, s. c) and 2.5% d-glucose 
solution (equivalent to 5% initial bw/day, i. p) for 3 successive days. 
Rats of TP-induced HN group had free access to distilled water only 
during this phase of experiment with no access to food.  
In the 2nd phase of the experiment (days 4–6), animals of all groups 
had free access to food and tap water. In this phase, the normal 
group received saline; the other three groups received TP (0.1 
mg/kg/day, s. c.) as a stabilizing dose. Group 2 served as the HN-
control group; groups 3 and 4 were treated with GT (600 
mg/kg/day, p. o.) and 1 M sodium chloride solution (hypertonic 
saline, HtNaCl; 15 ml/kg/day, i. p.), respectively.  
Estimation of serum sodium level 
Blood samples were withdrawn from the retro-orbital plexus of each 
animal, under light diethyl ether anesthesia, following induction 
phase (on day 4), and one hour following the last drug 
administration in the treatment phase (on day 6). The blood was 
allowed to coagulate and then centrifuged, using a cooling centrifuge 
(Sigma and laborzentrifugen, 2k15, Germany), at 3000 rpm for 20 
min for serum separation. Serum sodium level was estimated using 
specific reagent kit (Stanbio Laboratory, USA). 
Measurement of locomotor activity 
On days 0, 4 and 6 of the experiment, locomotor activity was 
assessed by detecting rat movements using grid floor activity cage 
(Model no. 7430, Ugo-Basile, Italy). Interruptions of infrared beams 
were automatically detected during a 10 min test session. Beam 
interruption information was processed in the activity cage software 
to provide an index of horizontal movements [50, 51]. Change of the 
basal locomotor activity was calculated for each rat. 
Evaluation of pain reflex 
The delay in pain reactivity, as a neuronal reflex, was evaluated on 
days 0, 4 and 6 of the experiment using the hot-plate test (7280 Ugo 
Basile, Italy) according to the method described by Laviola and 
Alleva [52]. Change of the basal response to the nociceptive stimulus 
was calculated for each rat. 
Tissue sampling and estimation of brain inducible nitric oxide 
synthase (iNOS) and nitric oxide (NO) contents 
Directly after collecting the last blood sample in the experiment, rats 
were decapitated under light diethyl ether-anesthesia, and their 
brain was carefully isolated and dissected through the midline into 
two hemispheres. One brain hemisphere from each rat was 
immediately weighed and homogenized in ice-cold potassium 
chloride (1.15%; pH 7.4) to yield a 20% (w/v) tissue homogenate 
(using MPW–120 homogenizers, Med instruments, Poland). The 
homogenates were centrifuged using a cooling centrifuge (Sigma 
and laborzentrifugen, 2k15, Germany) at 4000 r. p. m for 10 min; the 
supernatant was used for biochemical estimation of brain content of 
iNOS, using iNOS ELISA kit (MyBioSource, USA), and NOx (nitrite and 
nitrate, stable metabolites of NO) utilizing an NOx concentration 
assay kit (Cayman chemical company, Germany).  
Histopathological examination of brain tissues 
The other brain hemisphere of each rat was removed and 
immediately placed in 10% formalin. Afterward, brains were 
sectioned coronally at six levels. Sections were stained with 
hematoxylin and eosin (H&E), and processed for light microscopy 
evaluation of neuronal density, edema, and inflammation. 
Statistical analysis 
All the values are presented as means±standard error of the means 
(SE). Comparisons between different groups were carried out using 
one-way analysis of variance (ANOVA) followed by Tukey’s multiple 
comparison post hoc tests. For behavioral parameters, square root 
transformed percent was calculated according to Jones et al. [53] 
then comparisons between different groups were carried out using 
the nonparametric one-way ANOVA followed by Dunn's multiple 
comparisons post hoc test. The difference was considered significant 
when p˂0.05. GraphPad prismsoftware (version 6) was used to carry 
out these statistical tests.  
RESULTS 
Serum sodium level 
Subcutaneous injection of TP produced stable HN demonstrated by 
decreased serum sodium level to 109.85±4.8 and 112.08±5.3 
mmol/l on days 4and 6, respectively. Treatment of rats with GT or 
HtNaCl corrected TP-induced HN (fig. 1). 
Saline, rats, treated with saline and represented the normal group; 
TP, rats treated with terlipressin and served as a hyponatremia 
(HN)-model group; TP-GT, rats with TP-induced HN treated with 
green tea; TP-HtNaCl, rats with TP-induced HN treated with 
hypertonic saline. 
a Significantly different from the normal group at the corresponding 
day at p<0.05. 
bSignificantly different from TP group at the corresponding day at 
p<0.05. 
Locomotor activity and Pain reflex 
Induction of HN in rats using TP was coupled with a decrease in 
the basal locomotor activity that was observed on days 4 and 6 
(table 1). A delay of the basal pain reflex was also observed 
following the induction phase (on day 4); however, no significant 
difference was observed in a TP-treated group on day 6 (table 2). 
Treatment of rats with GT improved that TP-induced decrease in 
locomotor activity; however, HtNaCl failed to do so (table 1). On 
the other hand, rats treated with GT showed a significant delay 
of the response to pain stimulus as compared to both normal and 
HN group (table 2). 
Hegazy et al. 




Fig. 1: Effects of TP-induced HN, and the co-administration of GT and HtNaCl on serum sodium level in rats 
Saline, rats treated with saline and represented the normal group; TP, rats treated with terlipressin and served as hyponatremia (HN)-model group; 
TP-GT, rats with TP-induced HN treated with green tea; TP-HtNaCl, rats with TP-induced HN treated with hypertonic saline. 
aSignificantly different from normal group at the corresponding day at p < 0.05., bSignificantly different from TP group at the corresponding day at p < 0.05. 
 
Table 1: Effects of TP-induced HN, and the co-administration of GT and HtNaCl on the locomotor activity of rats 
Groups Locomotor activity 
Count/10 min. Square-root-transformed % of basal activity 
Day 0 Day 4 Day 6 Day 4 Day 6 
Saline 162.40±13.43 179.80±11.91 178.60±7.81 1.06b±0.04 1.06b±0.03 
TP 118.60±25.24 55.20±16.70 80.40±15.36 0.69a±0.12 0.83a±0.02 
TP-GT 161.20±26.84 96.00±21.19 155.60±25.08 0.78a±0.09 0.98b±0.01 
TP-HtNaCl 123.40±10.09 73.80±14.35 70.20±8.50 0.76a±0.11 0.76a±0.08 
Saline, rats treated with saline and represented the normal group; TP, rats treated with terlipressin and served as a hyponatremia (HN)-model 
group; TP-GT, rats with TP-induced HN treated with green tea; TP-HtNaCl, rats with TP-induced HN treated with hypertonic saline. 
Data are presented as mean±SE., a Significantly different from the normal group at the corresponding day at p<0.05., bSignificantly different from TP 
group at the corresponding day at p<0.05. 
 
Table 2: Effects of TP-induced HN, and the co-administration of GT and HtNaCl on the response of rats to the nociceptive stimulus 
Groups Delay of pain reflex 
Nociceptive response (sec) Square-root-transformed % of basal response 
Day 0 Day 4 Day 6 Day 4 Day 6 
Saline 38.25±3.71 27.72±3.05 29.02±2.62 0.84b±0.07 0.86±0.06 
TP 24.30±4.25 31.06±3.58 26.56±3.38 1.20a±0.08 0.98±0.13 
TP-GT 26.58±2.60 35.38±4.51 38.38±5.61 1.13a±0.05 1.21ab±0.10 
TP-HtNaCl 33.25±2.36 39.30±4.18 34.18±3.33 1.06a±0.04 0.99±0.03 
Saline, rats treated with saline and represented the normal group; TP, rats treated with terlipressin and served as a hyponatremia (HN)-model 
group; TP-GT, rats with TP-induced HN treated with green tea; TP-HtNaCl, rats with TP-induced HN treated with hypertonic saline. 
Data are presented as mean±SE., a Significantly different from the normal group at the corresponding day at p<0.05., bSignificantly different from TP 
group at the corresponding day at p<0.05. 
 
Fig. 2: Effects of TP-induced HN, and the co-administration of GT and HtNaCl on brain contents of iNOS and NOx in rats 
Saline, rats treated with saline and represented the normal group; TP, rats treated with terlipressin and served as hyponatremia (HN)-model group; 
TP-GT, rats with TP-induced HN treated with green tea; TP-HtNaCl, rats with TP-induced HN treated with hypertonic saline., a Significantly different 
from normal group at p<0.05., bSignificantly different from TP group at p<0.05. 
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Brain iNOS and NO contents 
Treatment of rats with TP to induce HN had no effect on the brain 
contents of iNOS and NOx. Similarly, administration of GT to TP-
treated rats showed normal iNOS and NOxcontent; whereas, 
administration of HtNaCl increased brain iNOS and NOx content in 
rats with TP-induced HN (fig. 2). 
Histopathological examination of brain tissues 
The brain sections prepared from normal rats showed normal brain 
tissue with normal astrocytes and fibrillary background (fig. 3a), 
while those prepared from rats with TP-induced chronic HN 
indicated a marked glial brain edema (fig. 3b). Treatment of rats 
with GT markedly ameliorated the brain edema observed in rats 
with TP-induced chronic HN and restored the normal histological 
structures of brain tissues (fig. 3c). The brain sections prepared 
from rats with TP-induced chronic HN treated by HtNaCl revealed 
marked amelioration of brain edema; however, neuronal cell 
necrosis associated with congestion of cerebral blood vessel was 
detected (fig. 3d). 
 
 
Fig. 3: Photomicrographs of brain sections prepared from (a) a 
normal rat, (b) a rat with TP-induced chronic HN, (c) a rat with 
TP-induced chronic HN treated by GT, and (d) a rat with TP-
induced chronic HN treated by HtNaCl (H&E X 400) 
 
(a) Showing normal brain tissue with normal astrocytes and 
fibrillary background. (b) Showing marked glial brain edema 
(arrow). (c) Showing marked amelioration of the glial astrocytes and 
fibrillary background brain edema observed in rats with TP-induced 
chronic HN. (d) Showing neuronal cell necrosis (short arrow) 
associated with congestion of cerebral blood vessel (long arrow). 
DISCUSSION 
In the present study, injection of TP (0.2 mg/kg/day, s. c.) along with 
2.5% d-glucose solution (equivalent to 5% initial bw/day, i. p), for 3 
successive days, induced profound (<115 mmol/l) chronic (>48 h) 
HN that was evidenced by decreased serum sodium level on days 4 
and 6. A hypotonic dextrose solution was used as a source of 
electrolyte-free water to produce expansion of the extracellular fluid 
volume; while, TP was used as an antidiuretic agent to prevent the 
excretion of that electrolyte-free water for the entire period of the 
experiment. Both elements must be satisfied to induce HN [54]; 
since the administration of antidiuretic agent without water does 
not result in HN [55], and administration of electrolyte-free water in 
the absence of antidiuretic agent leads, only, to a large water 
diuresis [56]. TP is a long-acting analog of VP, the antidiuretic 
hormone [57]. Like VP, TP stimulates vascular vasopressin type 1 
(V1) receptor and renal tubular V2 receptor, resulting in 
vasoconstriction and renal free water reabsorption, respectively. 
However, TP has a relatively higher affinity for the V1 receptor and 
lower affinity to the V2 receptor compared to VP [58]. Nevertheless, 
in agreement with the finding of the present study, Krag et al. [59] 
reported that TP induces V2 receptor-mediated antidiuresis and 
induces a decrease in plasma sodium level. In the common 
experimental animal models of HN, VP has been used, either as 
multiple doses per day or as a continuous infusion via 
subcutaneously implanted osmotic minipump [60, 61]. Interestingly, 
a single daily dose of 0.2 mg/kg TP for three successive days induced 
chronic HN in the current model. The different pharmacokinetic 
properties of VP and TP explain this outcome. TP has a long duration 
of action and its effective half-life time is 6 h, whereas that of VP is 
only 6 min [58, 62]. For that, this TP-induced HN model that was 
established in our previous study with colleagues (unpublished data 
[49]), is less complicated than the common VP model. In addition, TP 
is available in the markets (glypressine; Ferring Company, 
Germany), while VP is not commercially available in all countries 
[62]. A stabilizing dose of TP (0.1 mg/kg/day, s. c.) was used for 
another three days following the induction phase. This regimen was 
carried out to prevent the spontaneous correction of chronic HN 
[48], and to simulate its clinical conditions [63]. The current TP-
induced HN resulted in neurological complications in rats evidenced 
by the deterioration of the locomotor activity and pain reflex and 
confirmed by the histopathological findings revealed a marked brain 
edema. The chronic locomotor deficit that persisted for 6 d, and the 
delay of pain reflex detected on the 4th day, in rats with TP-induced 
HN are parallel to some of the typical signs of hyponatremic 
encephalopathy found in patients with HN [14]. However, the 
improvement of the pain reflex on day 6 may be due to the gradual 
adaptation of the brain to HN by extruding organic solutes from 
their cytoplasm, which decreases the degree of cerebral edema by 
allowing intracellular osmolality to be equal to plasma osmolality 
without a large increase in cell water [64]. This explanation may be 
supported by the study established that the impaired response to 
pain stimuli in patients with HN occurs in the more advanced state 
of cerebral edema rather than that associated with a reduction of 
locomotor activity [11].  
Following the induction phase, administration of GT (600 
mg/kg/day, p. o), for 3 successive days, corrected the serum sodium 
level in rats. This protective effect of GT against HN may be 
attributed to its diuretic effect [25, 26, 28], as previous studies 
showed that diuretics are useful in controlling edematous 
hyponatremic states [65, 66]. Improvement of locomotor activity 
was also observed in GT-treated rats; a finding that indicates a 
neuroprotective effect of GT against TP-induced hyponatremic 
encephalopathy. This conclusion was confirmed by the outcome of 
the histopathological investigation that revealed a marked 
improvement of TP-induced brain edema in the GT-treated group. In 
addition, Michna et al. [67] reported a direct stimulatory effect of 
oral administration of green tea and caffeine on locomotor activity in 
mice.  
On the other hand, delayed response to the nociceptive stimulus was 
noticed in GT-treated rats; though it was normal in untreated rats 
with TP-HN. This finding may be explained by the stated analgesic 
effect of GT [68, 69]. 
Administration of HtNaCl in the present study corrected HN itself 
but not its effect on locomotor activity. Actually, administration of 
high concentrations of NaCl results in a rapid correction of serum 
sodium level, which causes a serious cerebral demyelinating 
disorder known as osmotic demyelination syndrome (ODS) [70]. 
The clinical manifestations of ODS usually develop after a couple of 
days (average 4–6 d) following changes in sodium levels. Hence, the 
non-corrected locomotor activity observed with HtNaCl 
administration in the current study may be due to the beginning of 
the pathological changes in the brain that finally led to ODS. 
Fortunately, these findings were supported by the present 
histopathological observations of focal cellular necrosis with 
neovascular proliferation changes in the cerebral tissue of rats 
treated with HtNaCl, though the marked amelioration of brain 
edema. These observations are in agreement with those of previous 
studies showing that rapid correction of experimental animal 
models of HN with HtNaCl resulting in demyelinative lesions 
associated with focal cellular necrosis, gliovascular proliferation 
changes, and accumulation of active microglia [71-73]. These 
microglia have been found to produce proinflammatory cytokines, 
Hegazy et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 6, 253-259 
257 
which are potent inducers of iNOS [74]. The induction of iNOS by 
proinflammatory cytokines results in NO production, which 
aggravates oligodendroglial injury and demyelination [73]. In the 
present study, significantly high levels of iNOS and NOx were 
observed in the brain tissues of hyponatremic rats treated with 
HtNaCl; this indicated the presence of inflammatory cerebral 
damage coupled with excessive iNOS activation and NO production. 
The presence of this inflammatory cerebral damage in HtNaCl-
treated rats was also supported by the findings of the locomotor 
assessment and histopathological analysis. On the other hand, iNOS 
and NOx levels were normal in the brain tissues of rats with TP-
induced HN, indicating that, iNOS activation and NO production are 
not involved in the neuropathological features of hyponatremic 
encephalopathy. In accordance, studies that assessed iNOS activity 
in experimental animals with HN showed that iNOS activity 
increases only with rapid correction of chronic HN [71-73]. GT 
successfully managed brain iNOS and NOx levels after the correction 
of HN in the present study. This result, together with the findings of 
the histopathological investigation, demonstrated the neuro-
protective effect of GT against the pathological consequences of 
rapid correction of HN. The study of Nakagawa and Yokozawa [75] 
showed a direct scavenging of nitric oxide and superoxide by GT. On the 
other hand, Srivastava et al. [76] demonstrated that GT polyphenols act 
as potent inhibitors of nitric oxide generation independent of their 
antioxidant properties. Correspondingly, many studies reported the 
inhibition of iNOS expression by GT and GT polyphenols [77-80]; and 
considered it as an important mechanism underlying the 
neuroprotective effect of GT [81]. Choosing the 8 d duration for the 
experiment, before sacrificing the animals and isolation of brain for 
estimation of iNOS and NOx contents and histopathological examination, 
was guided by a previous study [60], to allow the development of the 
inflammatory cerebral damage that eventually leads to ODS, if any. In 
addition, another study [73] found that prominent accumulation of 
activated microglia was seen by 3 d after correction and that 
accumulation occurred parallel to the demyelinating changes. 
CONCLUSION 
In conclusion, the current study revealed that TP-induced HN rat 
model produced the main neuropathological features of human HN 
as manifested by the observed decrease of locomotor activity, delay 
of pain reflex, and development of the characteristic 
histopathological changes of the brain tissues. Administration of GT 
markedly improved TP-induced chronic HN in rats and protected 
against the neuropathological features that characterized 
hyponatremic encephalopathy and accompanied with its rapid 
correction. The study suggests GT as a therapeutic agent for 
protection against the neuropathological complications associated 
with chronic HN and its rapid correction. 
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